The Virtual Research Institute (WIB), operating within the structure of Łukasiewicz – PORT, is seeking partners for the commercialization of an innovative mRNA-based technology. The technology was developed by one of WIB’s research teams, and we are looking for a partner to help further develop and bring it to market.
The Virtual Research Institute (WIB) is a research funding program dedicated to projects with high commercialization potential, supported by a record budget of PLN 450 million provided by the Polish Ministry of Science and Higher Education. The program offers five years of funding to Poland’s top research teams working in the field of medical biotechnology. Selected by international experts, these teams are tasked with developing technologies that are ready for commercialization.
Collaboration Criteria for Business Partners
The invitation is open to companies with a proven track record in mRNA technologies, biotechnology, pharmaceuticals, or advanced medical technologies. WIB is not seeking an early-stage investor or an academic partner; rather, it is looking for an organization ready to play an active role in shaping the commercial and application-oriented development of the technology.
“We are looking for a partner who can contribute industry expertise and support the maturation of the technology toward specific research, clinical, or industrial applications. We aim to establish a collaborative partnership in which both parties have a meaningful influence on the technology’s development pathway and future direction. We are not seeking a company to adopt a ready-made solution. Rather, we are looking for a partner to co-develop it with us. The selected partner will be able to actively shape the technology’s future applications from an early stage,” says Mikołaj Gurdała, Director of the Virtual Research Institute (WIB).
Intellectual Property Protection and Licensing Terms for the mRNA Technology
Key Information for Prospective Partners:
- The technology is covered by comprehensive intellectual property (IP) protection.
- The technology is free from complex licensing and institutional obligations for organizations seeking to implement it.
- Business partners will have a meaningful role in defining the technology’s future development priorities and application areas.
- The objective of the collaboration is to advance the technology’s Technology Readiness Level (TRL) and tailor it to specific research, clinical, or industrial applications.
- At this stage, the collaboration does not involve any financial commitments or transfers between the parties.
Detailed information — including a description of the technology, its current level of maturity, and potential application scenarios — is made available to interested parties upon execution of a Non-Disclosure Agreement (NDA).
Application Process and Collaboration Stages
Companies interested in obtaining further information and exploring potential areas of collaboration are invited to contact:
- e-mail: wib_komercjalizacja@port.lukasiewicz.gov.pl
- or directly with the director of the WIB program, Mikołaj Gurdała.
Following the execution of the NDA, the next step will be a Memorandum of Understanding (MoU), which will outline the general framework and principles of the potential collaboration.
WIB reserves the right to select partners for further development and commercialization activities.
